Sunitinib is a targeted drug of several generations

Sunitinib is indicated for the treatment of adult patients with gastrointestinal stromal tumors (GIST) after disease progression on (or intolerance to) mesylate [imatinib], for the treatment of patients with advanced renal cell carcinoma (pNET) (pNET) in adult patients with unresectable locally advanced or metastatic disease. Targeted drugs are generally drugs used to treat tumors, and sunitinib is a second-generation targeted drug.

Sunitinib adverse events were considered manageable, with a low incidence of serious adverse events . The most common adverse events associated with sunitinib treatment were fatigue, diarrhea, nausea, anorexia, hypertension, yellowing of the skin, hand-foot skin reaction, and stomatitis. In the placebo-controlled Phase III GIST study, adverse events that occurred more frequently with sunitinib than with placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, fatigue, altered taste, and constipation.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.